Swiss Quality of Life and Health Care Impact Assessment in a Real-World Erenumab-Treated Migraine Population: Results over 2 years.

ABSTRACT:

Objectives/background

This prospective, multicenter, noninterventional cohort study evaluated the impact of erenumab on the quality of life and migraine-related impairment of adult patients with migraine, as well as the drug's tolerability in a real-world setting over 2 years. Erenumab, a fully human monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland for prophylactic treatment of adult patients with migraine in July 2018.

Methods

Adult patients with chronic or episodic migraine who received erenumab treatment as per Swiss label were enrolled from 19 sites across Switzerland between February 2019 and November 2022. Inclusion criteria were defined as the following: a migraine diagnosis per International Classification

SUBMITTER: Gantenbein AR 

PROVIDER: S-EPMC12266637 | biostudies-literature | 2025 Jul-Aug

REPOSITORIES: biostudies-literature